Paris – 2 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs , today extended warm congratulations to Oncodesign, an innovative biotechnology company dedicated to discovering new approaches to cancer and other serious illnesses for which no effective treatments are known, on its successful admission to trading on Alternext in Paris.
Founded by Philippe Genne in Dijon in 1995, Oncodesign is dedicated to accelerating the discovery of new, personalized and effective treatments for patients suffering from cancer. The company’s business model centres on two strategic activities: (1) experimentation through preclinical evaluation of new anticancer therapies on behalf of pharmaceutical and biotech companies, and (2) discovery of new therapeutic molecules, in particular a new generation of kinases, working independently or in partnership with large pharma groups such as Sanofi, Ipsen and UCB. To achieve these goals, Oncodesign draws on cutting-edge solutions that combine science and technology. The company holds a unique position within its market, including solid recognition from over 500 clients around the globe.
Oncodesign (ticker symbol: ALONC) was listed through the admission to trading of 4,390,640 existing shares making up the company’s equity and the sale of 1,749,394 new shares issued under a Global Offering , including full exercise of the extension option. The over-allotment option was also fully exercised, with 77,882 shares sold.
The offering was a resounding success with French and international investors, both institutional and retail. Total demand was €23.5 million, including an €11.6 million Global Placement and an €11.9 million Open Price Public Offering. The IPO raised €12.8 million altogether, with 40% allocated to individual investors.
The admission and issue price of Oncodesign shares was set at €7.34 per share, at the high end of the indicative price range. The company’s market capitalisation stood at around €44.5 million on the issue date.
“We welcome Oncodesign, an innovative international standard-setter in preclinical evaluation and discovery of anticancer treatments, to the market. The success of its IPO with both institutional investors and individuals illustrates the enormous appeal of biotech stocks. Oncodesign will benefit from the assistance of EnterNext’s experts and Euronext’s unique market model for both listing and trading. We are delighted to support the bold and innovative strategy of this company and the many fast-growing businesses listed on Euronext markets,” said Eric Forest, Chairman and CEO of EnterNext.
Oncodesign’s founder, Chairman and CEO Philippe Genne, added: “Our successful listing on Alternext Paris opens a new and critical stage in our growth. It has brought us both the financial resources we need and increased visibility to accelerate our discoveries of new, targeted anticancer therapies that will help treat many patients.”